Public Release: 

Scientists find new gene fault behind ovarian cancer

Cancer Research UK

Women who carry an inherited fault in the gene BRIP1 are over three times more likely to develop ovarian cancer than those without the fault, according to a study published in the Journal of the National Cancer Institute*.

Around 18 women in every 1,000 develop ovarian cancer, but this risk increases to around 58 women in every 1,000 for women with a fault in the BRIP1 gene. It's estimated that one in every 1,000 UK women have the gene fault.

This is because faults in the gene mean the cell cannot properly repair its DNA, causing genetic damage to build up, leading to cancer.

The study, led by Cancer Research UK scientists from the University of Cambridge, UCL and Imperial College London, also showed that women who carried the BRIP1 gene mutation were more likely to be diagnosed with an aggressive cancer, at a later stage and tended to be diagnosed at an older age.

The researchers compared the genes of more than 8,000 white European women - including around 3,250 women diagnosed with ovarian cancer, 3,400 women who did not have cancer and 2,000 women who had a family history of the disease.

Professor Paul Pharoah, professor of cancer epidemiology at the Cancer Research UK Cambridge Institute, said: "Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatest risk.

"Finding these women will help us prevent more cancers and save lives. This would be important in a disease like ovarian cancer, which tends to be diagnosed at a late stage when the chances of survival are worse."

Each year in the UK around 7,100 women are diagnosed with ovarian cancer and more than 4,200 women die from the disease.

Nell Barrie, Cancer Research UK's senior science information manager, said: "Research like this, which looks at inherited genetic changes and how they can affect a woman's risk, is vital. We urgently need ways to detect ovarian cancer early, as the cancer is often diagnosed when it's too late for effective treatment because the cancer has already spread. We hope this research will lead to a reliable way to spot women at a high risk, so they can be monitored to find any signs of the disease at an early stage."


For media enquiries contact Emily Head in the Cancer Research UK press office on 020 3469 6189 or, out of hours, on 07050 264 059.

Notes to editor:

Ramus et al. Mutations in the BRIP1, BARD1, PALB2 and NBN genes in women with ovarian cancer. Journal of the National Cancer Institute. DOI: 10.1093/jnci/djv214.

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit Follow us on Twitter and Facebook.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.